AFP-Derived Peptides Which Stop Breast Cancer Growth
Abstract
The peptide, EMTPVNPG, derived from the third domain of alpha-fetoprotein was synthesized and was found to inhibit estrogen-stimulated growth of immature mouse uterus and estrogen-dependent proliferation of MCF-7 human breast cancer xenografts with an activity similar to that of its parent protein. However, the biological activities of the peptide diminished as a function of time in storage, even when it was in the lyophilized state. Studies suggested that this peptide aggregated during storage to form inactive species. Therefore, we designed analogs of this peptide with the intent of minimizing aggregation and enhancing structural stability. In this annual report, we report two analogs that retain biological activity, even during prolonged storage. These analogs were a linear octapeptide EMTOVNOG (0 is 4-hydroxproline) that was generated by substituting 4-hydroxyproline for proline, and a cyclic nonapeptide, cyclo-(EMTOVNOGQ), that was generated by adding glutamine in the C-terminal position of EMTOVNOG, followed by cyclization.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2001
- Accession Number
- ADA396385
Entities
People
- Fassil Mesfin
- James A. Bennett
Organizations
- Albany Medical College